Could you two clowns stop making up blcht,and wait to see what happens.We all know there is questions with the poster,but also with the company.As usuual you are spinning and guessing and have no background to comment. here is one that rings true
You make an interesting point, but looking at Fig 4 it actually seems like something was at best mislabeled. If you look week to week there are earlier weeks with fewer patients than later weeks, suggesting they did not impute missing values and/or allowed subjects who missed a rating to continue on. That would suggest possible inclusion of possible protocol villagers, precisely why a PP analysis is rarely used. In any event, per other posts, what AF missed, including the above, is that if a PP analysis was specified there is no problem. If it was not, there is no dispute from the poster that different populations were used for the primary versus other endpoints, and that could be an issue. Finally, you are mistaken in assuming that the 128 patients in a PP population would have to overlap with the 128 patients in the mITT populations.
The piano player analyzes the data! lol! regarding the secondary endpoints "Zacks reported that Insmed will report these endpoints by December.".. I thought that was the Insmeds job? and "final data" was to be presented at the NACF ...so where did you get that stuff? ... Is this new like the quiet period?
SShhhhhh... cant talk till Nov 5! , that gives my hedge fund friends 10+ days to .....
September 30, 2013, before the opening of the stock market on Tuesday, November 5, 2013.
Will Lewis, President and Chief Executive Officer, and Andy Drechsler, Chief Financial Officer, will host a conference call for investors beginning at 8:30 a.m. ET on Tuesday, November 5,
The EU will get the complete data and the risks the side effects of using the drug are unknown.If you have been in biotech ,you have seen many a company go sailing along and the FDA completely gleans the data and finds something wrong,and that happens ALOT.
1-2 day event or downtrend started?
terry_insm: Probed $14.37 twice......third time the charm?
The downtrend line has not been broken but the 14.37 was. That is now resistance, we shall see how or if the chart develops.Good Luck
" This is a standard quite period that every company has to adhere to"
Insmed has to adhere to financial matters before earnings release,not data from a trial that has nothing to do with the call................ "The shorts are the longs- believe it"
Careful,broke support. I believe Insmed analysts( Lazard oh please) about as much as "The Street".It doesnt matter who is right or wrong now,it matters what the smart money is doing. Insmeds S.I. is around 25%+, and that is a fact we can all agree on.Good Luck
ps- loaded on X______
Probed .37 twice......third time the charm?
Companies who have nothing to hide do not hide when they release important data.
Some have stated there is missing data or results with mumbojumbo.I dont know but the company is acting very suspicious.I noted a couple of CC ago, Will Lewis was very deliberate in quickly jumping to NTM at every chance.......shorts ? what shorts? YTD +110% and happy to wait and see....
INSM below $14.37 close and they will commit, Cindy knows -) they will churn it before Congrats on PKPR
He nailed it ...I think he works at LAZARD!!
terry_insm • Oct 20, 2013
INSM - the Lazard "reiterates" on Thursday indicator? - )
Congrats on PRKR
Feuerstein is pointing out as others have is that the data is incomplete and wont comment on why.
We will let scientist types discuss the data which you just made up your opinion.
Jesse, I'll be patient.ALL Bios say they want to be a stand alone.....until someone (especially a hedge fund manager is offered a good premium.) Insmed is not a buyout candidate because of unknowns, approvals NTM data etc. The Zacks article was old and the data presented was the hype that become a nuthin last week (except for a heads up tweet). Insmed has told you they do not plan to trial or to file in the U.S. You are either a complete fool or a liar., and lastly "bashers" or "shorts" are bad guys to you but since Insmed is down 80% since you got here, you may want to listen... Have a nice day
Reality check Aug 30 INSM $15.21 Oct 21 $15.21. and 100 posts from those who took no profits waiting for $25 soon! Ignore on 1 trade and Surfs up! INSM chart looks very good but the overall Market is squinky Good Luck
Premarket= Looks like some really read that NACF poster,not blindly predicted fabulous things.
kvncmcdd(blueeyedcatch /biowatchman etc), zippy ( lux /dorian) and fudfighter 4 ( b_leagured/blasedp31) really
should listen,theyve been wrong for 9 years.YTD + 110% and Im so amused Im laughing all the way to the bank
redvh2003 is one of the honest Buy and Hold posters who put his numbers around an average of 11 dollars, (most here are averaged in here $11. "pure cash value) and showed the returns around 10% a year.Bio investing always does better taking profits and waiting for a pullback with a startup like Insmed.